The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.
The company has developed a proof-of-concept single-pore sensor that it anticipates integrating into a prototype testing platform this year.
The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
To market its analyte specific reagents, syndromic enteric panels, and other tests, the firm is building a US-based sales organization.
Clinical investigators have used Longhorn Vaccines and Diagnostics' qPCR approach in a study to detect M. tuberculosis DNA in the mouths of people at high risk for subclinical TB.
Developers pointed to some success, but they also noted that more at-home tests need to demonstrate higher levels of performance and affordability.
Companies developing tests for cancer therapy selection, therapy monitoring, and screening received most of the private investment, funding experts said.